Advertisement

Topics

Therachon’s TA-46 receives FDA and EMA orphan drug designation for achondroplasia

19:00 EDT 21 Jun 2017 | Pharmaceutical Technology

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted orphan drug designation to Therachon’s TA-46 therapy for treating patients with achondroplasia.

Original Article: Therachon’s TA-46 receives FDA and EMA orphan drug designation for achondroplasia

NEXT ARTICLE

More From BioPortfolio on "Therachon’s TA-46 receives FDA and EMA orphan drug designation for achondroplasia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...